Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model (2024)
- Authors:
- USP affiliated authors: BRITTO, LUIZ ROBERTO GIORGETTI DE - ICB ; FERREIRA, ANA FLAVIA FERNANDES - ICB
- Unidade: ICB
- DOI: 10.3389/fnana.2024.1511951
- Subjects: FISIOLOGIA; DOENÇA DE PARKINSON; ATROFIA DE MÚLTIPLOS SISTEMAS; CITOCINAS; DOENÇAS NEURODEGENERATIVAS; MODELOS ANIMAIS DE DOENÇAS; CAMUNDONGOS; IMUNOHISTOQUÍMICA; ELISA EM ANIMAL
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Neuroanatomy
- ISSN: 1662-5129
- Volume/Número/Paginação/Ano: v. 18, art. 1511951, 12 p., 2024
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
BIANCHETTI, Maria Eduada Goulart e FERREIRA, Ana Flávia Fernandes e BRITTO, Luiz Roberto Giorgetti de. Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model. Frontiers in Neuroanatomy, v. 18, p. 12 , 2024Tradução . . Disponível em: https://doi.org/10.3389/fnana.2024.1511951. Acesso em: 31 mar. 2026. -
APA
Bianchetti, M. E. G., Ferreira, A. F. F., & Britto, L. R. G. de. (2024). Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model. Frontiers in Neuroanatomy, 18, 12 . doi:10.3389/fnana.2024.1511951 -
NLM
Bianchetti MEG, Ferreira AFF, Britto LRG de. Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model [Internet]. Frontiers in Neuroanatomy. 2024 ; 18 12 .[citado 2026 mar. 31 ] Available from: https://doi.org/10.3389/fnana.2024.1511951 -
Vancouver
Bianchetti MEG, Ferreira AFF, Britto LRG de. Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model [Internet]. Frontiers in Neuroanatomy. 2024 ; 18 12 .[citado 2026 mar. 31 ] Available from: https://doi.org/10.3389/fnana.2024.1511951 - The transient receptor potential melastatin 2: a new therapeutical target for Parkinson’s disease?
- Therapeutic potential of KATP channels in the attenuation of Parkinson's disease pathogenesis and progression: a review
- Mitochondrial abnormalities in neurological disorders
- Deletion of the transient receptor potential melastatin 2 gene mitigates the 6-hyydroxydopamine-induced Parkinson’s Disease–Like Pathology
- The role of interleukin-17 in neurological disorders
- Most utilized rodent models for Alzheimer’s and Parkinson’s disease: a critical review of the past 5 years
- Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology
- Lithium and disease modification: a systematic review and meta-analysis in Alzheimer's and Parkinson’s disease
- Irisin reduces neurodegeneration and neuroinflammation in the 6-hydroxydopamine rat model of Parkinson’s disease
- Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
